S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones
S&P 500   4,604.37
DOW   36,247.87
QQQ   392.17
Dozens of animals taken from Virginia roadside zoo as part of investigation
Trading Experts Call It “The Perfect Tesla Trade” (Ad)
Military-themed brewery wants to open in a big Navy town. An ex-SEAL is getting in the way
Cows in Rotterdam harbor, seedlings on rafts in India; are floating farms the future?
New CBOE “special perk” helps traders target income every weekend (Ad)
Agriculture gets its day at COP28, but experts see big barriers to cutting emissions
Shohei Ohtani joins big-money club with massive contract with Los Angeles Dodgers
New CBOE “special perk” helps traders target income every weekend (Ad)
Consumer product agency issues warning on small magnetic balls linked to deaths
Elon Musk restores X account of conspiracy theorist Alex Jones

GSK Stock Price, News & Analysis (NYSE:GSK)

$35.94
-0.06 (-0.17%)
(As of 12/8/2023 ET)
Compare
Today's Range
$35.84
$36.09
50-Day Range
$34.18
$37.56
52-Week Range
$33.20
$38.32
Volume
1.51 million shs
Average Volume
2.81 million shs
Market Capitalization
$73.59 billion
P/E Ratio
9.66
Dividend Yield
3.70%
Price Target
$24.44

GSK MarketRank™ Stock Analysis

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
32.0% Downside
$24.44 Price Target
Short Interest
Healthy
0.18% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
N/A
News Sentiment
0.63mentions of GSK in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-2.29%
From $3.93 to $3.84 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.76 out of 5 stars

Medical Sector

723rd out of 932 stocks

Pharmaceutical Preparations Industry

343rd out of 431 stocks


GSK stock logo

About GSK Stock (NYSE:GSK)

GSK plc, formerly known as GlaxoSmithKline plc, is a British multinational pharmaceutical company headquartered in Brentford, London. It operates in three main business areas: pharmaceuticals, vaccines and consumer healthcare products. The company has a global presence, operating in over 150 countries and employing over 94,000 people worldwide.

GSK has a long history of innovation and has been responsible for developing some of the world's most important medicines, including treatments for asthma, HIV/AIDS and cancer. The company is also committed to global health initiatives, focusing on improving access to essential medicines in developing countries.

Emma Walmsley has been the CEO of GSK since 2017, becoming the first female CEO of a major pharmaceutical company. She has been instrumental in transforming the company's operations and has led a significant restructuring effort to simplify the business and focus on key growth areas. The management team includes several other key executives, including Dr. Hal Barron, former President of Research and Development, now a Non-Executive Director and Luke Miels, Chief Commercial Officer.

GSK's financial performance has been mixed in recent years. The company's revenue has been relatively flat over the past few years, and rising R&D costs and the impact of COVID-19 on sales have impacted profitability. In Q2 - Q4 of 2022, the company's stock price dropped nearly 40% concerning long-term shareholders. This stock has underperformed the broader market and many of its peers in the pharmaceutical industry. However, this also points to the fact that the stock is undervalued relative to its peers providing good value for would-be investors.

GSK has also undergone significant changes in ownership in recent years. In 2019, the company merged its consumer healthcare business with Pfizer's consumer healthcare business to create a new joint venture. GSK owns a majority stake in the joint venture, which is expected to generate significant cost savings and synergies.

The pharmaceutical industry is highly competitive, with a few major players dominating the market. GSK's primary competitors include Pfizer, Johnson & Johnson and Roche. The industry is also heavily regulated, with stringent drug safety and efficacy requirements.

One of the key trends in the industry is the shift toward personalized medicine, which involves developing treatments tailored to individual patients based on their genetic makeup. GSK has invested heavily in this area, focusing on oncology and rare diseases.

Despite the pharmaceutical industry's challenges, GSK has several growth opportunities in its core business areas. The company has a strong pipeline of new drugs and vaccines in development, including several potential blockbusters. GSK is also expanding its presence in emerging markets, where demand for healthcare products is growing rapidly.

In addition, the company has been exploring opportunities in digital health and artificial intelligence, which could transform how medicines are developed and delivered. GSK is also committed to sustainability and has set ambitious targets to reduce its environmental impact and improve access to healthcare in low-income countries.

The pharmaceutical industry is subject to a range of risks and challenges, including regulatory hurdles, patent expirations and intense competition. GSK is not immune to these risks and faces some specific challenges.

The COVID-19 pandemic is one of the biggest challenges facing GSK. Another risk is the potential for increased regulatory scrutiny. The pharmaceutical industry is pressured to demonstrate that its products are safe and effective. GSK has faced significant fines and penalties for regulatory violations.

GSK faces competition from established players in the industry and new entrants, particularly in digital health. As a result, the company will need to continue to invest in innovation and R&D to maintain its competitive position and drive growth in the future.

GSK Stock Price History

GSK Stock News Headlines

3 cheap 'stock'-ing stuffers Wall Street is bullish on (GSK)
These three companies have Wall Street feeling bullish and are trading under $10, making them ideal ‘stock'-ing stuffers for hard to shop for traders.
At £14, the GSK share price looks like a top bargain to me
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
GSK hopes for boost from two respiratory blockbusters
Getting_Ahead_of_Respiratory_Diseases_Slides
All the trading advice you’ve ever received boils down to this
All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.
GSK receives EU regualtory boost for bone marrow cancer drug
EU regulator backs GSK's bone marrow cancer therapy
See More Headlines
Receive GSK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for GSK and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Ex-Dividend for 10/12 Dividend
8/17/2023
Dividend Payable
10/12/2023
Last Earnings
11/01/2023
Ex-Dividend for 1/11 Dividend
11/16/2023
Today
12/09/2023
Fiscal Year End
12/31/2023
Dividend Payable
1/11/2024
Next Earnings (Estimated)
2/07/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
69,400
Year Founded
2000

Price Target and Rating

Average Stock Price Target
$24.44
High Stock Price Target
$24.44
Low Stock Price Target
$24.44
Potential Upside/Downside
-32.0%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
4 Analysts

Profitability

Net Income
$18.50 billion
Pretax Margin
22.61%

Debt

Sales & Book Value

Annual Sales
$36.28 billion
Cash Flow
$4.45 per share
Book Value
$5.79 per share

Miscellaneous

Outstanding Shares
2,047,520,000
Free Float
1,842,765,000
Market Cap
$73.59 billion
Optionable
Optionable
Beta
0.64

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for December 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Ms. Emma Natasha Walmsley (Age 53)
    CEO & Director
    Comp: $5.94M
  • Ms. Julie Belita Brown (Age 61)
    CFO & Executive Director
  • Ms. Shobie Ramakrishnan
    Chief Digital & Technology Officer
  • Mr. Tony Wood
    Chief Scientific Officer
  • Ms. Sarah Elton-Farr
    Head of Investor Relations
  • Mr. James Ford
    Senior VP & Group General Counsel of Legal & Compliance
  • Ms. Sally  JacksonMs. Sally Jackson
    Senior Vice President of Global Communications & CEO Office
  • Mr. David Simon Redfern BSc (Hons) (Age 57)
    CA, President of Corporate Development
  • Ms. Diana Conrad
    Chief People Officer
  • Mr. Philip C. Thomson
    President of Global Affairs














GSK Stock Analysis - Frequently Asked Questions

Should I buy or sell GSK stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for GSK in the last twelve months. There are currently 2 sell ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" GSK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in GSK, but not buy additional shares or sell existing shares.
View GSK analyst ratings
or view top-rated stocks.

What is GSK's stock price target for 2024?

4 analysts have issued twelve-month price objectives for GSK's shares. Their GSK share price targets range from $24.44 to $24.44. On average, they predict the company's share price to reach $24.44 in the next year. This suggests that the stock has a possible downside of 32.0%.
View analysts price targets for GSK
or view top-rated stocks among Wall Street analysts.

How have GSK shares performed in 2023?

GSK's stock was trading at $35.14 on January 1st, 2023. Since then, GSK shares have increased by 2.3% and is now trading at $35.94.
View the best growth stocks for 2023 here
.

Are investors shorting GSK?

GSK saw a decrease in short interest during the month of November. As of November 15th, there was short interest totaling 3,740,000 shares, a decrease of 6.5% from the October 31st total of 4,000,000 shares. Based on an average daily trading volume, of 3,680,000 shares, the days-to-cover ratio is presently 1.0 days. Currently, 0.2% of the shares of the stock are short sold.
View GSK's Short Interest
.

When is GSK's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 7th 2024.
View our GSK earnings forecast
.

How were GSK's earnings last quarter?

GSK plc (NYSE:GSK) posted its quarterly earnings data on Wednesday, November, 1st. The pharmaceutical company reported $1.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.09 by $0.17. The pharmaceutical company earned $10.32 billion during the quarter, compared to the consensus estimate of $9.72 billion. GSK had a net margin of 20.47% and a trailing twelve-month return on equity of 52.88%.

How often does GSK pay dividends? What is the dividend yield for GSK?

GSK declared a quarterly dividend on Wednesday, November 1st. Shareholders of record on Friday, November 17th will be paid a dividend of $0.3398 per share on Thursday, January 11th. This represents a $1.36 dividend on an annualized basis and a yield of 3.78%. The ex-dividend date is Thursday, November 16th.
Read our dividend analysis for GSK
.

Is GSK a good dividend stock?

GSK (NYSE:GSK) pays an annual dividend of $1.33 per share and currently has a dividend yield of 3.69%. The dividend payout ratio is 35.75%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, GSK will have a dividend payout ratio of 34.64% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for GSK.

What other stocks do shareholders of GSK own?

Based on aggregate information from My MarketBeat watchlists, some companies that other GSK investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Verizon Communications (VZ), Cisco Systems (CSCO), AbbVie (ABBV), Intel (INTC), Gilead Sciences (GILD), Walt Disney (DIS) and NVIDIA (NVDA).

Who are GSK's major shareholders?

GSK's stock is owned by many different retail and institutional investors. Top institutional investors include FMR LLC (0.88%), JTC Employer Solutions Trustee Ltd (0.61%), Primecap Management Co. CA (0.59%), Royal Bank of Canada (0.39%), Morgan Stanley (0.37%) and Equity Investment Corp (0.16%).
View institutional ownership trends
.

How do I buy shares of GSK?

Shares of GSK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NYSE:GSK) was last updated on 12/10/2023 by MarketBeat.com Staff

My Account -